切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2013, Vol. 01 ›› Issue (01) : 2 -8. doi: 10.3877/cma.j.issn.2095-5820.2013.01.001

述评

现在与未来的检验医学在医疗卫生中的重要作用
Graham H Beastall1,()   
  1. 1.International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Office, 20159 Milano, Italy
  • 收稿日期:2013-09-17 出版日期:2013-11-28
  • 通信作者: Graham H Beastall

The central role of laboratory medicine in healthcare: present and future

H Beastall Graham1,()   

  1. 1.International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Office, 20159 Milano, Italy
  • Received:2013-09-17 Published:2013-11-28
  • Corresponding author: H Beastall Graham
引用本文:

Graham H Beastall. 现在与未来的检验医学在医疗卫生中的重要作用[J/OL]. 中华临床实验室管理电子杂志, 2013, 01(01): 2-8.

H Beastall Graham. The central role of laboratory medicine in healthcare: present and future[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2013, 01(01): 2-8.

检验医学是医疗卫生中的一项医学专业。医疗卫生的未来发展趋势表明对诊断性检查提供的信息的依赖程度将越来越高,这意味着检验医学的重要作用将得到巩固。检验医学领导者的职责在于从当地医疗卫生环境中发展检验医学的中心地位,进而使患者能最大获益。临床实验室负责人的首要责任是通过国际标准实验室认可(例如ISO 15189)来确保各方面质量的持续改进。在此基础上,地区、国家及国际检验医学领导者需要为检验医学提供增值服务,来确保为患者个人或群体提供最适宜的传递、使用、开发和评估服务。对附加价值的简要诠释的缩写是“SCIENCE”,包括7个方面:标准化和一致性(standardisation and harmonisation)、临床效益(clinical effectiveness)、创新(innovation)、循证实践(evidence-based practice)、新项目应用(novel applications)、成本效益(cost effectiveness)和教育培训(education of others)。另一简单方法可用于评估实验室医学的发展,即通过三方面的框架结构(运营效率、患者管理及患者行为)对任何发展进行评估。这2种方法均可使复杂问题转变为简单且可衡量的结果。专业人员和患者则可从良好实践中分享未来检验医学发展的益处。

Laboratory medicine is a medical specialty at the centre of healthcare. Future trends in healthcare indicate increasing dependence on knowledge obtained from diagnostic investigations, meaning that the central role of laboratory medicine will be consolidated. Leaders in laboratory medicine have a professional responsibility to develop the centrality of laboratory medicine in their local healthcare setting in order to derive maximum benefit for patients. The first responsibility of the head of a clinical laboratory is to ensure the provision of continuous quality improvement across a wide range of parameters culminating in laboratory accreditation against an international standard such as ISO 15189. From that essential baseline the leadership of laboratory medicine at local, national and international level needs to‘add value’to ensure the optimal delivery, use,development and evaluation of the services provided for individuals and for groups of patients. A convenient tool to illustrate added value is use of the mnemonic‘SCIENCE’. This tool allows added value to be considered in seven domains: standardisation and harmonisation; clinical effectiveness; innovation; evidence-based practice;novel applications; cost effectiveness; education of others. A second simple tool may be used to assess the impact of developments in laboratory medicine. This tool evaluates any new development against a framework that comprises three dimensions: operational efficiency, patient management, and patient behaviour. The use of these two tools should help to rationalise a complex topic into simple, measurable outcomes. The profession and the patient will benefit from sharing examples of good practice in the future development of laboratory medicine.

图1 哈佛商业评论编辑定义的全球医疗卫生的发展趋势图 注:全球医疗卫生十二大发展趋势环绕时钟的设计,意味着发展趋势的变化会随时间而发生
图2 通过“SCIENCE”为检验医学带来附加价值的构成图
图3 评估检验医学价值的框架图 注:通过思考与评估其在运营效率、患者管理和患者行为三方面的影响力,以获得发展方面的综合改进价值
1
Report of the review of NHS pathology services in England. An independent review for the Department of Health. London: Department of Health, 2006.
2
Hallworth MJ. The ‘70% claim’: what is the evidence base?[J] Ann Clin Biochem, 2011, 48:487-488.
3
The Lewin Group, Inc. Laboratory medicine: a national status report.Falls Church,VA: The Lewin Group, Inc; 2008.
4
MaRS Discovery District. Life sciences: Molecular diagnostics.New tools for evidence-based medicine[N/OL]. 2009[2009-09-14].http://www.marsdd.com/wp- content/uploads/2011/ 02/MaRSReport-Molecular-Diagnostics.pdf.
5
Billings P. Three barriers to innovative diagnostics[J]. Nat Biotechnol,2006,24: 917-918.
6
Dillon K, Prokesch S. Megatrends in global health care[N/OL]. http://hbr.org/web/extras/insight-center/health-care/globaltrends/Accessed 14 September 2013.
7
Fraser CG. Biological variation: from principles to practice.2001:151pp AACC Press Washington, DC. 2011.
8
The International Organization for Standardization. ISO 15189-2012: Medical laboratories-particular requirements for quality and competence. 2012.
9
Bonini P, Plebani M, Ceriotti F, et al. Errors in laboratory medicine[J].Clin Chem, 2002, 48: 691-698.
10
Beastall GH. Adding value to laboratory medicine: a professional responsibility[J]. Clin Chem Lab Med, 2013,51:221-228.
11
McLawhon RW. Patient safety and clinical effectiveness as imperatives for achieving harmonization inside and outside the laboratory[J]. Clin Chem[J], 2011,57:936-938.
12
Magdal U, Dybkaer R, Olesen H. Properties and units in the clinical laboratory sciences, Part XXIII. The NPU terminology, principles and implementation-a user′s guide[J]. Clin Chem Lab Med, 2012,50:35-50.
13
Tate JR, Johnson R, Legg M. Harmonisation of laboratory testing[J].Clin Biochem Rev, 2012,33:81-84.
14
The International Organization for Standardization. ISO 17511:2003.In vitro diagnostic medical devices. Measurement of quantities in biological samples. Metrological traceability of values assigned to calibrators and control materials. 2003.
15
Barth JH. Selecting clinical quality indicators in laboratory medicine[J].Ann Clin Biochem, 2012,49:257-261.
16
Barlow IM. Are biochemistry interpretative comments helpful? Results of a general practitioner and nurse practitioner survey[J]. Ann Clin Biochem, 2008,45:88-90.
17
Genzen JR, Tormey CA. Pathology consultation on reporting critical of values[J]. Am J Clin Pathol, 2011,135:505-513.
18
Verbocket-van de Venne WP, AAkre KM, Watine J, et al. Reflective testing: adding value to laboratory testing[J]. Clin Chem Lab Med,2012,50:1249-1252.
19
Li P, Challand GS. Experience with assessing the quality of comments on clinical biochemistry reports[J]. Ann Clin Biochem, 1999,36:759-765.
20
Linnet K, Bossuyt PM, Moons KG, et al. Quantifying the accuracy of a diagnostic test or marker[J]. Clin Chem, 2012,58:1292-1301.
21
Beastall GH. The modernisation of pathology and laboratory medicine in the UK. Networking into the future[J]. Clin Biochem Rev,2008,29:3-10.
22
Madabhushi A, Doyle S, Lee G, et al. Integrated diagnostics: a conceptual framework with examples[J]. Clin Chem Lab Med,2010,48:989-998.
23
Price CP. Evidence-based laboratory medicine: is it working in practice?[J] Clin Biochem Rev, 2012,33:13-19.
24
Oosterhuis WP, Bruns DE, Watine J, et al. Evidence-based guidelines in laboratory medicine: Principles and methods[J]. Clin Chem,2004,50:806-818.
25
Hood L, Friend SH. Predictive, personalised, preventive, participatory(P4) cancer medicine[J]. Nat Rev Clin Oncol, 2011,8:184-187.
26
Agarwal A. Do companion diagnostics make economic sense for drug developers?[J] N Biotechnol, 2012,29:695-708.
27
Novis DA, Konstantakos G. Reducing errors in the practices of pathology and laboratory medicine. An industrial approach[J]. Am J Clin Path, 2006,126 Suppl 1: S30-35.
28
Smellie WS. Demand management and test request rationalization[J].Ann Clin Biochem, 2012,49(Pt 4):323-336.
29
Thomas RE, Croal BL, Ramsay C, et al. Effect of enhanced feedback and brief educational reminder messages on laboratory test requesting in primary care: a cluster randomised trial[J]. Lancet, 2006,367:1990-1996.
30
Price CP, Jones RG. The challenges in commissioning laboratory medicine(pathology) services[J]. J Manage Market Health, 2008,1:166-178.
31
Anonychuk A, Beastall G, Shorter S, et al. A framew1ork for assessing the value of laboratory diagnostics. Health Care Managem Forum,2012,25:S4-S11.
32
Lee DW, Neumann PJ, Rizzo JA. Understanding the medical and nonmedical value of diagnostic testing[J]. Val Health, 2010,13:310-314.
No related articles found!
阅读次数
全文


摘要